معرفی
Bernard Masereel is a senior academic and research leader at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Unite de recherche en pharmacologie et toxicologie clinique. He is a key member of the Clinical Pharmacology Research Group and contributes to the NAmur MEdicine & Drug Innovation Center and the Namur Thrombosis and Hemostasis Center. His work is internationally recognized, with over 379 research outputs and an h-index of 42.
His research focuses on medicinal chemistry and pharmacological innovation, particularly in cancer therapy and anticoagulant development. He specializes in the design and synthesis of beta-carboline and boronic compounds for applications such as boron neutron capture therapy and the inhibition of serine proteases involved in thrombosis. His fingerprint includes core topics like synthesis, cancer, receptors, and inhibition, reflecting a strong commitment to drug discovery and evaluation.
His recent publications from 2017 to 2022 demonstrate a consistent focus on anti-cancer compounds, proteomic investigations, and analytical methodologies in pharmaceutical quality control. These works highlight interdisciplinary approaches combining organic synthesis, biochemical assays, and clinical applications.
Bernard Masereel has supervised numerous research projects and students, contributing significantly to training and innovation in pharmaceutical sciences. He has been involved in key initiatives such as the Télévie and BNCT projects, demonstrating leadership in translational research.
He is active in organizing and participating in scientific conferences, including the Franco-Belgian Medicinal Chemistry Days and workshops on anticoagulants and drug design. His work supports Sustainable Development Goals related to health and innovation.
